Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 35 publications
Gain of function NOTCH4 variants disrupt angiogenesis in systemic sclerosis.
Journal: Annals of the rheumatic diseases
Published: April 24, 2025
Comparative Efficacy of Immunosuppressive Therapies in the Treatment of Diffuse Cutaneous Systemic Sclerosis.
Journal: ACR open rheumatology
Published: November 13, 2024
Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation for Diffuse Cutaneous Systemic Sclerosis: Identifying Disease Risk Factors for Toxicity and Long-Term Outcomes in a Prospective, Single-Arm Trial.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: August 05, 2024
Racial variability in immune responses only partially explains differential systemic sclerosis disease severity.
Journal: Annals of the rheumatic diseases
Published: January 02, 2024
Factors associated with life satisfaction in systemic sclerosis: Examining the moderating roles of social support and spiritual well-being.
Journal: Journal of scleroderma and related disorders
Published: June 07, 2023
Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: February 22, 2023
Autologous Stem Cell Transplantation With Intensity Modulated Total Body Irradiation Conditioning for Systemic Sclerosis.
Journal: International journal of radiation oncology, biology, physics
Published: November 20, 2022
Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial.
Journal: The Lancet. Rheumatology
Published: December 30, 2021
Adipose-Derived Regenerative Cell Transplantation for the Treatment of Hand Dysfunction in Systemic Sclerosis: A Randomized Clinical Trial.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: November 10, 2021
Anti-vinculin antibodies in scleroderma (SSc): a potential link between autoimmunity and gastrointestinal system involvement in two SSc cohorts.
Journal: Clinical rheumatology
Published: April 12, 2020
Responsiveness of the University of California Los Angeles Scleroderma Clinical Trial Consortium gastrointestinal tract 2.0 (UCLA-SCTC-GIT 2.0)to change in scleroderma patients.
Journal: Journal of scleroderma and related disorders
Published: February 10, 2020
HLA and autoantibodies define scleroderma subtypes and risk in African and European Americans and suggest a role for molecular mimicry.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: December 25, 2019
Last Updated: 09/26/2026